רווח למניה בשנים עשר החודשים האחרונים: Purple Biotech Ltd (PPBT)

Fierce competition with pharma behemoths for FDA approval is driving high volatility, as evidenced by the rolling net income per share. The value -28.30 shows the current magnitude of this indicator. Purple Biotech (PPBT) is currently focusing on R&D without commercial sales, and its growth potential is based on trials of agents against stomach tumor resistance.

Global partnerships of Purple Biotech (PPBT) allow the company to mitigate Israel's geopolitical risks while maintaining operational resilience. The metric is calculated as the ratio of total net income to the total number of shares outstanding. This calculation determines the real return per share, eliminating distortions from issuance. The investor assesses the business's sensitivity to the external environment without waiting for quarterly reports. The trend in per-share profit changes over the last 12 months confirms sales effectiveness.